Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.79 |
| ▸ | MAPT | P10636 | 3/20 | 0.79 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.79 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.79 |
| ▸ | NR3C1 | P04150 | 9/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.63 |
| ▸ | PGR | P06401 | 4/20 | 0.63 |
| ▸ | USP2 | O75604 | 2/20 | 0.63 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.63 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.63 |
| ▸ | MLNR | O43193 | 1/20 | 0.63 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.63 |
| ▸ | PPARG | P37231 | 1/20 | 0.63 |
| ▸ | MMP1 | P03956 | 6/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | AR | P10275 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4100798 | 0.91 | LMNA (0.82) | LMNAMAPTSMN1; SMN2NPSR1NR3C1 | |
| SCHEMBL568167 | 0.89 | LMNA (0.88) | LMNAMAPTSMN1; SMN2NPSR1NR3C1 | |
| SCHEMBL28099304 | 0.89 | LMNA (0.88) | LMNAMAPTSMN1; SMN2NPSR1NR3C1 | |
| Clobetasone Butyrate SCHEMBL29572705 | 0.88 | LMNA (1.00) | LMNAMAPTSMN1; SMN2NPSR1NR3C1 | |
| Clobetasone Butyrate SCHEMBL448850 | 0.88 | LMNA (1.00) | LMNAMAPTSMN1; SMN2NPSR1NR3C1 | |
| Clobetasone Butyrate SCHEMBL14339619 | 0.88 | LMNA (1.00) | LMNAMAPTSMN1; SMN2NPSR1NR3C1 | |
| Clobetasone Butyrate SCHEMBL36599 | 0.88 | LMNA (1.00) | LMNAMAPTSMN1; SMN2NPSR1NR3C1 | |
| Clobetasone Butyrate SCHEMBL29410388 | 0.88 | LMNA (1.00) | LMNAMAPTSMN1; SMN2NPSR1NR3C1 | |
| Clobetasone Butyrate SCHEMBL11124627 | 0.88 | LMNA (1.00) | LMNAMAPTSMN1; SMN2NPSR1NR3C1 | |
| Clobetasone Butyrate SCHEMBL11750078 | 0.88 | LMNA (1.00) | LMNAMAPTSMN1; SMN2NPSR1NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1755616-A2 | TREATMENT OF OPHTHALMIC CONDITIONS WITH MINERALCORTICOIDS | Advanced Ocular Systems Limited (AU) | 2007-02-28 | — | — | EP | claimed |
| WO-2005099715-A9 | TREATMENT OF OPHTHALMIC CONDITIONS WITH MINERALCORTICOIDS | RETMED PTY LTD | 2007-02-15 | — | — | WO | claimed |
| US-20050245497-A1 | Treatment of ophthalmic conditions | EYE CO PTY LTD (AU) | 2005-11-03 | — | — | US | claimed |
| WO-2005099715-A2 | TREATMENT OF OPHTHALMIC CONDITIONS WITH MINERALCORTICOIDS | RETMED PTY LTD. (AU) | 2005-10-27 | — | — | WO | claimed |
| CN-114026113-A | Selective targeting of ubiquitin and ubiquitin-like E1 activating enzymes by structurally stabilized peptides | 丹娜法伯癌症研究院 | 2022-02-08 | — | — | CN | disclosed |
| EP-1755616-B1 | Treatment of exudative retinopathy with mineralcorticoids | ADVANCED OCULAR SYSTEMS LTD (AU) | 2013-08-14 | — | — | EP | disclosed |
| EP-1755616-A2 | TREATMENT OF OPHTHALMIC CONDITIONS WITH MINERALCORTICOIDS | Advanced Ocular Systems Limited (AU) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005099715-A9 | TREATMENT OF OPHTHALMIC CONDITIONS WITH MINERALCORTICOIDS | RETMED PTY LTD | 2007-02-15 | — | — | WO | disclosed |
| US-20050245497-A1 | Treatment of ophthalmic conditions | EYE CO PTY LTD (AU) | 2005-11-03 | — | — | US | disclosed |
| WO-2005099715-A2 | TREATMENT OF OPHTHALMIC CONDITIONS WITH MINERALCORTICOIDS | RETMED PTY LTD. (AU) | 2005-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245497-A1 | Treatment of ophthalmic conditions | MC2R, NR3C2, PTGIR | LMNA 3426/4885MAPT 2777/4885SMN1; SMN2 4778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.